Clerq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 33: 307-20. 2009.
Das K, Clark AD Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J. Med. Chem. 47:2550-60. 2004.
Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 4:236-48.2005.
Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell. 67:1211-21. 1991.
Kearney BP, Mittan A, Sayre J, et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir [abstract #A-1617]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2003 September 14-17; Chicago, Illinois.
Khalilieh SG, Yee KL, Sanchez RI, et al. Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects. J Clin Pharmacol. 58(8):1044–52. 2018.
Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab. Dispos. 35: 1657-63. 2007.
Ramanathan S, Mathias AA, German P, et al. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Journal Clin Pharmacokinet. 50:229-44. 2011.
Hazuda D, Iwamoto M, Wenning L. Emerging pharmacology: inhibitors of human immunodeficiency virus integration. Annu. Rev. Pharmacol. Toxicol. 49:377–394. 2009.
Rodríguez-Nóvoa S, Labarga P, Pablo D, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 24:1064-6, 2010.
Marzolini C, Telenti A, Decosterd L, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS, 15:71-5, 2001.
Read TR, Carey D, Mallon P, et al. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. AIDS. 16:2222-3. 2009.
Tsuchiya, K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz-concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun., 319:1322-6.2004.
Gibbons S, Robinson L, Dickinson L et al. Therapeutic drug monitoring of atazanavir in routine clinical settings in the UK. 7th ICDTHI, 14-18 Nov, 2004, Glasgow. Abstract P274.
Wenning L, Hwang1 E, Nguyen1 B-Y, et al. Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Raltegravir (RAL) in Phase III Studies in Treatment Experienced HIV-Infected Patients Following 48 Weeks of Treatment [abstract #H-4054]. 48th Annual ICAAC/IDSA 46th Annual Meeting; 2008 October 25-28. Washington DC, USA.
Hluhanich R, Kinkade A, Margot NA, et al. HIV integrase inhibitors do not exert a post-antibiotic effect despite slow dissociation from IN-DNA complexes in vitro [abstract H930]. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009 September 12-15; San Francisco, California.
Yagura H, Watanabe D, Nakauchi T, et al. Effect of dolutegravir plasma concentration on central nervous system side effects. Conference on Retroviruses and Opportunistic Infections; 2017 February 13-16. Seattle, USA.
The Department of Health and Human Services : Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, revised on May 1, 2014.
Yagura H, Watanabe D, Kushida H, et al. Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1. BMC Infect Dis. 17:622. 2017.